{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yan L"],"funding":["The key project of food safety of the Science and Technology Ministry of China","National Natural Science Foundation of China"],"pagination":["e9306"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7350924"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8"],"pubmed_abstract":["Added risk portended by diabetes in addition to hypertension has been related to an amplification of endothelial dysfunction. β-blockers are widely used for cardiovascular diseases and improve the endothelial function compared with a placebo. However, the effect of β-blockers on the endothelial progenitor cells (EPCs) function in diabetes is still unknown. Five β-blockers (metoprolol, atenolol, propranolol, bisoprolol, and nebivolol) were tested in EPC functional screening. Metoprolol improved EPC function significantly among the five β-blockers and was chosen for the <i>in vivo</i> tests in STZ induced diabetic mice. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements were performed using the Endo-PAT2000 device in diabetic patients. Metoprolol, but not other β-blockers"],"journal":["PeerJ"],"pubmed_title":["Metoprolol rescues endothelial progenitor cell dysfunction in diabetes."],"pmcid":["PMC7350924"],"funding_grant_id":["81703627","81872660","2017YFC1600204","81803643"],"pubmed_authors":["Li JF","Yan L","Deng YP","Qing TL","Dai XY","Dong YF","Chen JK","Han X","Tian YJ","Gao FY","Zhu JB","Shi WJ","Zhang XF"],"additional_accession":[]},"is_claimable":false,"name":"Metoprolol rescues endothelial progenitor cell dysfunction in diabetes.","description":"Added risk portended by diabetes in addition to hypertension has been related to an amplification of endothelial dysfunction. β-blockers are widely used for cardiovascular diseases and improve the endothelial function compared with a placebo. However, the effect of β-blockers on the endothelial progenitor cells (EPCs) function in diabetes is still unknown. Five β-blockers (metoprolol, atenolol, propranolol, bisoprolol, and nebivolol) were tested in EPC functional screening. Metoprolol improved EPC function significantly among the five β-blockers and was chosen for the <i>in vivo</i> tests in STZ induced diabetic mice. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements were performed using the Endo-PAT2000 device in diabetic patients. Metoprolol, but not other β-blockers","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-04-19T21:09:28.214Z","creation":"2025-02-19T00:51:41.389Z"},"accession":"S-EPMC7350924","cross_references":{"pubmed":["32704438"],"doi":["10.7717/peerj.9306"]}}